MedTrace Logo

Excimer Laser, Serum Markers & Psoriasis

NCT02165657 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2021-07-16

No results posted yet for this study

Summary

The overall aims for this study are to determine whether UVB excimer laser treatment of psoriasis affects serum inflammatory markers, and to assess hyperpigmentation and erythema with excimer laser treatment.

The investigators hypothesize that treatment of psoriasis with UVB delivered via 308 nm excimer laser will decrease the levels of serum inflammatory markers. The investigators hypothesize that treatment will decrease plaque erythema and will result in minimal hyperpigmentation.

Conditions

Interventions

DEVICE

Excimer laser treatment

Excimer laser irradiation twice a week for up to 20 treatments.

Sponsors & Collaborators

  • Photomedex

    collaborator UNKNOWN

  • University Hospitals Cleveland Medical Center

    lead OTHER

Principal Investigators

  • Margaret Bobonich, NP · University Hospitals Cleveland Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2017-03-31
Completion
2017-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02165657 on ClinicalTrials.gov